SCHEMBL8626313

SCHEMBL8626313

Cc1cccc(C)c1OC(CCC(P(=O)(O)O)S(=O)(=O)O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 5/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
SLC6A2 P23975 4/20 0.38
SLC6A4 P31645 4/20 0.38
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2D6 P10635 3/20 0.38
CHRM1 P11229 2/20 0.38
TSHR P16473 2/20 0.38
ADRA2B P18089 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HRH1 P35367 2/20 0.38
OPRM1 P35372 2/20 0.38
DRD3 P35462 2/20 0.38
OPRK1 P41145 2/20 0.38
HTR2B P41595 2/20 0.38
SLC6A3 Q01959 2/20 0.38
KCNH2 Q12809 2/20 0.38
KLF10 Q13118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8622280 0.88 SLC6A2 (0.52) ACP3SLC6A2SLC6A4CYP1A2CYP3A4
SCHEMBL8623419 0.83 SLC6A4 (0.46) ACP3SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL8622068 0.83 SLC6A9 (0.48) ACP3SLC6A4KMT2A
SCHEMBL8621492 0.82 ACP3 (0.44) ACP3L3MBTL1SLC6A4OPRM1KMT2A
SCHEMBL8619830 0.81 SLC6A2 (0.52) ACP3SLC6A2SLC6A4CYP1A2CYP3A4
SCHEMBL8623971 0.78 PPARG (0.39) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL8620195 0.77 F2 (0.39) ACP3SLC6A4PPARA
SCHEMBL8623278 0.77 FDFT1 (0.42) ACP3SLC6A4PPARA
SCHEMBL8947061 0.76 SLC6A4 (0.39) SLC6A2SLC6A4KMT2A
SCHEMBL8623463 0.75 ACP3 (0.34) ACP3SLC6A2SLC6A4CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US claimed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US claimed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP claimed
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US disclosed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed